A new study using PET scans on the brains of older individuals shows a three-fold higher risk of mild cognitive impairment (MCI) among those with elevated levels of amyloid-beta, a proteinaceous material associated with neurodegeneration. MCI is a known risk factor for Alzheimer's disease.
Two large meta-analyses in JAMA shed light on the link between Alzheimer s disease and amyloid beta (A-Î²). The key findings indicate that it is likely to take up to 30 years of amyloid deposition before clear signs of dementia are manifest but such deposits are not diagnostic.
Recently, the FDA has approved new PET tracers as clinical tools to estimate brain amyloid burden in patients being evaluated for cognitive impairment or dementia. And these new tracers - tau-protein tracers - may be